{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:58:18Z","timestamp":1791849498312,"version":"4.3.4"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T00:00:00Z","timestamp":1472774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Col\u00b7legi Oficial de Farmac\u00e8utics de Barcelona","award":["COFB-JG-15052014"],"award-info":[{"award-number":["COFB-JG-15052014"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0161527","type":"journal-article","created":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T17:40:27Z","timestamp":1472838027000},"page":"e0161527","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis"],"prefix":"10.1371","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-5496","authenticated-orcid":true,"given":"Ariadna","family":"P\u00e9rez-Ricart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Galicia-Basart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Alcalde-Rodrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfons","family":"Segarra-Medrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep-Maria","family":"Su\u00f1\u00e9-Negre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Bruno","family":"Montoro-Ronsano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,9,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options","volume":"6","author":"J Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl. 3","key":"ref2","first-page":"S1","article-title":"National Kidney Foundation K\/DOQI clinical practice guidelines for bone metabolism in chronich kidney disease","volume":"42","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 113","key":"ref3","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"76","year":"2009","journal-title":"Kidney Int"},{"issue":"6","key":"ref4","first-page":"793","article-title":"Cinacalcet hydrochloride for the treatment of hyperparathyroidism Expert Opin","volume":"14","author":"N Verheyen","year":"2013","journal-title":"Pharmacother"},{"key":"ref5","unstructured":"Food and Drug Administration. Sensipar<sup>\u00ae<\/sup>, 2004; revised November 2014. Available from<ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021688s20_21_22lbl.pdf\" xlink:type=\"simple\">http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021688s20_21_22lbl.pdf<\/ext-link> Accessed January 29, 2016"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/j.ajkd.2008.09.021","article-title":"A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis","volume":"53","author":"M Chonchol","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"DW Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","article-title":"Expressing the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate with Standardized Serum Creatinine Values","volume":"53","author":"AS Levey","year":"2007","journal-title":"Clin Chem"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ajkd.2005.04.013","article-title":"Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis","volume":"46","author":"C Charytan","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1440-1797.2011.01530.x","article-title":"Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis","volume":"17","author":"J Montenegro","year":"2012","journal-title":"Nephrology"},{"key":"ref11","unstructured":"Miguel JL, Romero S, Madero R, Martinez J, Azorin S, Selgas R. \u00bfControla el cinacalcet el hiperparatiroidismo secundario en pacientes con insuficiencia renal cr\u00f3nica estadio V no dializados? V Interantional Symposium Advances in Bone and Mineral Disorders in CKD, Oviedo, 2009."},{"key":"ref12","unstructured":"Ramos A, Albalate M, Martin C, Manrique MP, Fernandez B, Riani G et al. Induccion a la remision clinica de hiperparatiroidismo secundario (HPTH 2\u00b0) con cinacalcet en enfermedad renal cronica (ERC) estadios 4 y 5 sin hemodialisis. 39 Congreso Sociedad Espa\u00f1ola de Nefrolog\u00eda, Pamplona, 2009."},{"key":"ref13","first-page":"801","article-title":"Experience with cinacalcet for secondary hyperparathyroidism in patients with chronic kidney disease stage III and IV","volume":"1","author":"T Forslund","year":"2009"},{"issue":"4","key":"ref14","first-page":"443","article-title":"Analysis of efficacy and factors that impact the response of secondary hyperparathyroidism to cinacalcet in haemodialysis patients","volume":"30","author":"P Segura","year":"2010","journal-title":"Nefrologia"},{"key":"ref15","unstructured":"National Institute for Health and Clinical Excellence. Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy NICE technology appraisal guidance 117, January 2007. Available from <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.nice.org.uk\/guidance\/ta117\/resources\/guidance-cinacalcet-for-the-treatment-of-secondary-hyperparathyroidism-in-patients-with-endstage-renal-disease-on-maintenance-dialysis-therapy-pdf\" xlink:type=\"simple\">https:\/\/www.nice.org.uk\/guidance\/ta117\/resources\/guidance-cinacalcet-for-the-treatment-of-secondary-hyperparathyroidism-in-patients-with-endstage-renal-disease-on-maintenance-dialysis-therapy-pdf<\/ext-link>. Accessed July 29, 2015"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.farma.2010.10.008","article-title":"Evaluaci\u00f3n retrospectiva de la efectividad y seguridad de cinacalcet para el tratamiento de hiperparatiroidismo secundario dependiendo del valor basal de paratohormona intacta","volume":"36","author":"G Mercadal","year":"2012","journal-title":"Farm Hosp"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"GA Block","year":"2004","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2215\/CJN.01040308","article-title":"Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: The ACHIEVE study results","volume":"3","author":"S Fishbane","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1093\/ndt\/gfn026","article-title":"Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism","volume":"23","author":"GA Block","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/ndt\/gfs568","article-title":"Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism","volume":"28","author":"P Ure\u00f1a-Torres","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2215\/CJN.03591006","article-title":"The OPTIMA Study: assessing a new cinacalcet (Sensipar\/ Mimpara) treatment algorithm for secondary hyperparathyroidism","volume":"3","author":"P Messa","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1523-1755.2005.67139.x","article-title":"Achieving NKF-K\/DOQITM bone metabolism and disease treatment goals with cinacalcet HCl","volume":"67","author":"SM Moe","year":"2005","journal-title":"Kidney International"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","article-title":"Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study","volume":"16","author":"JS Lindberg","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1093\/ndt\/gfp144","article-title":"Cinacalcet and achievement of the NKF\/K-DOQITM recommended target values for bone and mineral metabolism in real-world clinical practice\u2014the ECHO observational study","volume":"24","author":"P Ure\u00f1a","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"c109","DOI":"10.1159\/000319882","article-title":"Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients: an observational study in routine clinical practice","volume":"118","author":"J Bover","year":"2011","journal-title":"Nephron Clin Pract"},{"issue":"1","key":"ref26","first-page":"46","article-title":"Characteristics of bone mineral metabolism in patients with stage 3\u20135 chronic kidney disease not on dialysis: results of the OSERCE study","volume":"33","author":"JL G\u00f3rriz","year":"2013","journal-title":"Nefrologia"},{"issue":"Suppl 1","key":"ref27","first-page":"i36","article-title":"Potential future uses of calcimimetics in patients with chronic kidney disease","volume":"1","author":"M Chonchol","year":"2008","journal-title":"NDT Plus"},{"issue":"3","key":"ref28","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality Risk for Dialysis Patients With Different Levels of Serum Calcium, Phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"F Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"ref29","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/jama.2011.308","article-title":"Serum Levels of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death and Cardiovascular Disease in Individuals With Chronic Kidney Disease","volume":"305","author":"SC Palmer","year":"2011","journal-title":"JAMA"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4330\/wjc.v6.i4.115","article-title":"Coronary artery calcification in chronic kidney disease","volume":"6","author":"T Stomp\u00f3r","year":"2014","journal-title":"An Update World J Cardiol"},{"issue":"7","key":"ref31","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/ncpneph0821","article-title":"Cinacalcet should not be used to treat secondary hyperparathyroidism in stage 3\u20134 chronic kidney disease","volume":"4","author":"DW Coyne","year":"2008","journal-title":"Nat Clin Pract Neph"},{"issue":"6","key":"ref32","first-page":"697","article-title":"Effectiveness of treatment with oral paricalcitol in patients with pre-dialysis chronic kidney disease","volume":"31","author":"JG Herv\u00e1s","year":"2011","journal-title":"Nefrologia"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0161527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T02:46:18Z","timestamp":1588992378000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0161527"}},"subtitle":[],"editor":[{"given":"Abelardo I","family":"Aguilera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,9,2]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,9,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0161527","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,2]]}}}